Featured Research

from universities, journals, and other organizations

'Cool' factor separates e-cigarettes from nicotine inhalers, study finds

Date:
June 3, 2014
Source:
Springer
Summary:
Why are e-cigarettes so popular among Americans who want to quit smoking, even though so little is known about their safety or effectiveness? The answer lies in their marketing -- they are simply 'cooler' than nicotine inhalers. "E-cigarettes have the potential to be important nicotine delivery products because of their high acceptance and perceived benefit, but more data are needed to evaluate their actual efficacy and safety," emphasized the lead researcher.

Why are e-cigarettes so popular among Americans who want to quit smoking, even though so little is known about their safety or effectiveness? The answer lies in their marketing -- they are simply "cooler" than nicotine inhalers. So says Michael Steinberg of the Rutgers Robert Wood Johnson Medical School in the USA, leader of a pilot study about the perception and use of these nicotine delivery devices. The findings appear in the Journal of General Internal Medicine, published by Springer.

Nicotine inhalers work when nicotine vapor is breathed in and absorbed through cells in the mouth lining, and studies have proven their safety and ability to help people to quit smoking. Despite being approved by the US Food and Drug Administration since 1997, these pharmaceutical products are rarely used. On the other hand, the electronic cigarette, or e-cigarette, is very popular despite limited data about its safety and benefits.

No regulatory evaluation has been done on this device, by which vaporized nicotine is inhaled through the heating of a nicotine-containing solution. Its visible "vapor" can be inhaled and exhaled.

Steinberg's team conducted a crossover trial during which 38 current smokers from New Jersey tried out the e-cigarette and the nicotine inhaler over a period of three days each. The participants rated the e-cigarette to be more acceptable and "cool," and judged it to be more helpful and effective in the process of trying to quit smoking.

The e-cigarette also provided superior satisfaction and physical reward compared to the inhaler, and was even on par with the participants' own tobacco cigarettes.

Seventy-six percent of the participants said they would indeed use an e-cigarette to help them quit. Eighteen percent (seven of the 38 participants) did not smoke at all during the three-day test period using the e-cigarette, while only 10 percent (four participants) refrained while using the inhaler.

Moreover, knowledge and perceptions about the e-cigarette are much stronger than those about the nicotine inhaler.

Steinberg's team believes this is because of its better marketing on television, the internet, on Facebook and Twitter. In contrast, very little advertising is done for the inhaler.

"E-cigarettes have the potential to be important nicotine delivery products because of their high acceptance and perceived benefit, but more data are needed to evaluate their actual efficacy and safety," emphasizes Steinberg. He believes physicians, as trusted sources of health information, should be aware of these issues so that they can adequately inform patients about the pros and cons involved. "Physicians have the potential to be an important source for answers about e-cigarettes that may influence the public's perceptions and use of these products."


Story Source:

The above story is based on materials provided by Springer. Note: Materials may be edited for content and length.


Journal Reference:

  1. Michael B. Steinberg, Mia Hanos Zimmermann, Cristine D. Delnevo, M. Jane Lewis, Parth Shukla, Elliot J. Coups, Jonathan Foulds. E-Cigarette Versus Nicotine Inhaler: Comparing the Perceptions and Experiences of Inhaled Nicotine Devices. Journal of General Internal Medicine, 2014; DOI: 10.1007/s11606-014-2889-7

Cite This Page:

Springer. "'Cool' factor separates e-cigarettes from nicotine inhalers, study finds." ScienceDaily. ScienceDaily, 3 June 2014. <www.sciencedaily.com/releases/2014/06/140603135805.htm>.
Springer. (2014, June 3). 'Cool' factor separates e-cigarettes from nicotine inhalers, study finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/06/140603135805.htm
Springer. "'Cool' factor separates e-cigarettes from nicotine inhalers, study finds." ScienceDaily. www.sciencedaily.com/releases/2014/06/140603135805.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins